---
title: "Upstream Bio, Inc. (UPB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/UPB.US.md"
symbol: "UPB.US"
name: "Upstream Bio, Inc."
industry: "Biotechnology"
---

# Upstream Bio, Inc. (UPB.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [upstreambio.com](https://upstreambio.com) |

## Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Ph...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:12.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 124 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 26.82% |  |
| Net Profit YoY | -140.18% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.10 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 415.02M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.80M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -124.45% | E |
| Profit Margin | -4366.77% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 26.82% | A |
| Net Profit YoY | -140.18% | E |
| Total Assets YoY | 68.11% | A |
| Net Assets YoY | 71.64% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -2.06% | D |
| OCF YoY | 26.82% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 3.22% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Upstream Bio, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-124.45%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4366.77%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "26.82%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-140.18%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "68.11%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "71.64%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-2.06%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "26.82%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "3.22%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.06 | 301/606 | - | - | - |
| PB | 1.10 | 92/606 | 3.74 | 2.20 | 1.11 |
| PS (TTM) | 148.27 | 270/606 | 505.83 | 331.22 | 205.06 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 75% |
| Overweight | 2 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.68 |
| Highest Target | 75.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/UPB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/UPB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/UPB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.